Next 10 |
home / stock / anpcy / anpcy news
2024-04-24 03:16:41 ET More on Angle Plc, AstraZeneca, etc. What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca Imfinzi l...
ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE / April 24, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutio...
Proprietary cell recovery device and method eliminates over 70% of CTC cell loss from standard microscopy techniques increasing assay sensitivity GUILDFORD, SURREY / ACCESSWIRE / April 22, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circula...
PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCE CTC HER2 assay being developed for HER2 targeted drugs and antibody drug conjugates presented at internationally renowned AACR Annual Meeting 2024 GUILDFORD, SURREY / ACCESSWIRE / April 8, 2024 / ANG...
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCE ANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Portrait HER2 assay GUILDFORD, SURREY / ACCESSWIRE / March 22, 2024 / ANGLE plc (AIM:AG)(O...
REVIEW PAPER ON MOLECULAR ANALYSIS OF PARSORTIX CTC HARVEST HIGHLIGHTS POTENTIAL UTILITY IN PRECISION ONCOLOGY Paper published in the journal "Current Issues in Molecular Biology" special issue: advanced solutions for cancer therapy GUILDFORD, SURREY / ACCESSWIRE / January 22, 2024 / AN...
Pilot study for ANGLE's Portrait HER2 assay in Phase II study of HER2 targeting antibody-drug conjugate, BB-1701 GUILDFORD, SURREY / ACCESSWIRE / January 2, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnosti...
USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG DISCOVERY Harvested CTCs reveal gene expression profile associated with development and progression of brain metastasis in melanoma Researchers suggest such profiling could prove to be "pivotal" to prescribing m...
GUILDFORD, SURREY / ACCESSWIRE / December 11, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is pleased to announce that Berenberg will ...
ANGLE LAUNCHES PORTRAIT+ CTC KIT AT SAN ANTONIO BREAST CANCER SYMPOSIUM ANGLE's Portrait+ CTC staining kit combines the power of Parsortix ® technology with an optimised immunofluorescent assay The test is designed for highly accurate, repeatable, and precise results allowing ...
News, Short Squeeze, Breakout and More Instantly...
Angle Plc Surrey ADR Company Name:
ANPCY Stock Symbol:
OTCMKTS Market:
ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE / April 24, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutio...
Proprietary cell recovery device and method eliminates over 70% of CTC cell loss from standard microscopy techniques increasing assay sensitivity GUILDFORD, SURREY / ACCESSWIRE / April 22, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circula...
PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCE CTC HER2 assay being developed for HER2 targeted drugs and antibody drug conjugates presented at internationally renowned AACR Annual Meeting 2024 GUILDFORD, SURREY / ACCESSWIRE / April 8, 2024 / ANG...